OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -118.36% | 24.00% | 39.37% | 32.96% | 61.89% |
| Total Depreciation and Amortization | -6.90% | -49.64% | -60.49% | -65.53% | -67.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 488.51% | -20.71% | -26.79% | 24.29% | -71.94% |
| Change in Net Operating Assets | 66.73% | 78.00% | 85.15% | 51.02% | -104.48% |
| Cash from Operations | 11.20% | 30.71% | 50.24% | 53.55% | 48.81% |
| Capital Expenditure | -83.63% | 30.89% | 70.14% | 89.02% | 93.53% |
| Sale of Property, Plant, and Equipment | -98.87% | -100.00% | 87.80% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 126.75% | 126.75% | 126.75% | -- |
| Cash from Investing | 45.06% | 89.17% | 103.51% | 110.02% | 78.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -71.79% | 20.32% | 86.42% | 91.70% | 91.81% |
| Issuance of Common Stock | 100.85% | 14.28% | 14.15% | -57.80% | -57.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -382.02% | -382.02% | -382.02% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -320.37% | -69.79% | -26.00% | 11.41% | 11.59% |
| Cash from Financing | 67.64% | -21.08% | -15.76% | -66.20% | -65.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.41% | 42.97% | 70.47% | 27.52% | 14.40% |